Ipsen pays €12m tasquinimod milestone for prostate cancer trial
This article was originally published in Scrip
Executive Summary
Active Biotech of Sweden has received a milestone payment of from Ipsen for an "undisclosed clinical event" related to the 10TASQ10 study in metastatic castration-resistant prostate cancer (mCRPC) patients for tasquinimod, CEO Tomas Leanderson told Scrip.